In this video, health-care analyst David Williamson looks at Vivus' first-quarter results and breaks it down into key takeaways for investors in both Vivus and its competitor Arena. Watch and find out why shares of the obesity-drug maker went up despite missing sales estimates and what it means now that Arena has received DEA scheduling.